🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 165 of 857 · Phase 3 first, then by program name

  1. SOF

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HCV Infection

    phase 3 small molecule completed

    2 trials

  2. SOF/VEL

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 3 small molecule completed

    3 trials

  3. SOF/VEL/VOX

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 3 small molecule completed

    1 trial

  4. SOTATERCEPT, SOTATERCEPT, sotatercept, sotatercept

    Merck Sharp and Dohme

    ​​Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  5. SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL

    Amgen

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  6. SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  7. SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  8. SP, chloroquine, amodiaquine, primaquine, artesunate

    United Therapeutics Europe Ltd

    Malaria

    phase 3 small molecule completed

    1 trial

  9. SP-102

    Semnur Pharmaceuticals

    Lumbosacral Radicular Pain

    phase 3 small molecule active

    3 trials

  10. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  11. SPD465

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  12. SPD476

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  13. SPD476 (1.2g)

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  14. SPD476 (mesalazine)

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  15. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  16. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  17. SPD489

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  18. SPD489

    Takeda

    ADHD

    phase 3 small molecule terminated

    1 trial

  19. SPD489

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  20. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  21. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials

  22. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  23. SPD489 40mg

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  24. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources